Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

abstract：:To improve the expression levels of transgenes in malignant hematopoietic cells, we developed a novel adenoviral-alphavirus hybrid vector Ad5/F11p-SFV-GFP that contains a Semliki Forest Virus (SFV) replicon and chimeric fibers of Ad5 and Ad11p. Ad5/F11p-SFV-GFP infected >95% of K562, U937 or Jurkat cells and 23.65% of...

journal_title：Cancer gene therapy

authors： Yang Y,Xiao F,Lu Z,Li Z,Zuo H,Zhang Q,Li Q,Wang H,Wang LS

更新日期：2013-08-01 00:00:00

abstract：:The targeted expression of transgenes is one of the principal goals of gene therapy, and it is particularly relevant for the treatment of brain tumors. In this study, we examined the effect of the overexpression of human gas1 (growth arrest specific 1) and human p53 cDNAs, both under the transcriptional control of a p...

journal_title：Cancer gene therapy

authors： Benítez JA,Arregui L,Vergara P,Segovia J

更新日期：2007-10-01 00:00:00

abstract：:Although the high transfection efficiency with adenovirus in vitro is well documented, it is still not clear whether adenoviral vectors are effective in vivo in solid tumor models. In our preliminary experiment, transduction of tumor tissue was limited to just around the injection site after intratumoral injection of ...

journal_title：Cancer gene therapy

authors： Lee SG,Yoon SJ,Kim CD,Kim K,Lim DS,Yeom YI,Sung MW,Heo DS,Kim NK

更新日期：2000-10-01 00:00:00

abstract：:CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity. As there are higher T(reg) levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcri...

journal_title：Cancer gene therapy

authors： Morse MA,Hobeika A,Serra D,Aird K,McKinney M,Aldrich A,Clay T,Mourich D,Lyerly HK,Iversen PL,Devi GR

更新日期：2012-01-01 00:00:00

abstract：:Multiple myeloma (MM) accounts for 10% of hematological malignant disorders. Its refractory nature indicates the necessity of developing novel therapeutic modalities. Since interleukin 6 (IL-6) is one of the major growth factors for MM cells, we expressed suppressor of cytokine signaling-1 (SOCS-1), one of the blockad...

journal_title：Cancer gene therapy

authors： Yamamoto M,Nishimoto N,Davydova J,Kishimoto T,Curiel DT

更新日期：2006-02-01 00:00:00

abstract：:We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cel...

journal_title：Cancer gene therapy

authors： Pitzer C,Schindowski K,Pomer S,Wirth T,Zöller M

更新日期：1999-03-01 00:00:00

abstract：:Endothelial cells and endothelial cell precursors encoding a therapeutic gene have induced antitumor responses in preclinical models. Culture of peripheral blood provides a rich supply of autologous, highly proliferative endothelial cells, also referred to as blood outgrowth endothelial cells (BOECs). The aim of this ...

journal_title：Cancer gene therapy

authors： Bodempudi V,Ohlfest JR,Terai K,Zamora EA,Vogel RI,Gupta K,Hebbel RP,Dudek AZ

更新日期：2010-12-01 00:00:00

abstract：:Immune responses to tumor-associated antigens are often dampened by a tumor-induced state of immune anergy. Previous work has attempted to overcome tumor-induced T-cell anergy by the direct injection of vectors carrying the genes encoding one of a variety of cytokines. We hypothesised that the polyclonal stimulation o...

journal_title：Cancer gene therapy

authors： Paul S,Regulier E,Rooke R,Stoeckel F,Geist M,Homann H,Balloul JM,Villeval D,Poitevin Y,Kieny MP,Acres RB

更新日期：2002-05-01 00:00:00

abstract：:The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential...

journal_title：Cancer gene therapy

authors： Piao Y,Jiang H,Alemany R,Krasnykh V,Marini FC,Xu J,Alonso MM,Conrad CA,Aldape KD,Gomez-Manzano C,Fueyo J

更新日期：2009-03-01 00:00:00

abstract：:In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid-based "splice-activated gene expression" (pSAGE) vectors was generated, which contain minigene cassettes composed of various combinations of the t...

journal_title：Cancer gene therapy

authors： Hayes GM,Carpenito C,Davis PD,Dougherty ST,Dirks JF,Dougherty GJ

更新日期：2002-02-01 00:00:00

abstract：:Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines,...

journal_title：Cancer gene therapy

authors： Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

更新日期：2000-02-01 00:00:00

abstract：:The antitumor activity of a recombinant canarypox virus expressing wild type murine p53 (ALVAC-p53) was investigated in two murine syngeneic tumors harboring an endogenous p53 mutation (CMS4 and TS/A). Direct intratumor injections of ALVAC-p53 in CMS4 pre-established subcutaneous tumors induced total tumor regression ...

journal_title：Cancer gene therapy

authors： Odin L,Favrot M,Poujol D,Michot JP,Moingeon P,Tartaglia J,Puisieux I

更新日期：2001-02-01 00:00:00

abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

journal_title：Cancer gene therapy

authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

更新日期：2007-01-01 00:00:00

abstract：:Mammary carcinomas that develop in C3 (1)/SV40 T- antigen (TAg) transgenic mice have lost the p53-mediated induction of p21, leading to increased cellular proliferation and significant elevations of cyclins and Cdks. To test whether p21 could serve as a target for anticancer therapy for this mammary cancer model, a re...

journal_title：Cancer gene therapy

authors： Shibata MA,Yoshidome K,Shibata E,Jorcyk CL,Green JE

更新日期：2001-01-01 00:00:00

abstract：:In this study, we investigated the safety and efficacy in cancer patients of a single intra-tumor injection of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene (AdV/TK) followed by systemic administration of ganciclovir (GCV). In 18 patients with malignant tumors refractory to standard...

journal_title：Cancer gene therapy

authors： Xu F,Li S,Li XL,Guo Y,Zou BY,Xu R,Liao H,Zhao HY,Zhang Y,Guan ZZ,Zhang L

更新日期：2009-09-01 00:00:00

abstract：:Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA...

journal_title：Cancer gene therapy

authors： Paul S,Bizouarne N,Dott K,Ruet L,Dufour P,Acres RB,Kieny MP

更新日期：2000-04-01 00:00:00

abstract：:To investigate a novel suicide gene for nasopharyngeal carcinoma (NPC) therapy, the yCDglyTK gene was constructed by fusing yeast cytosine deaminase (CD) and herpes simplex type 1 thymidine kinase. The expression of the yCDglyTK gene was detected by RT-PCR and Western blotting, and its bioactivity was demonstrated by ...

journal_title：Cancer gene therapy

authors： Xia K,Liang D,Tang A,Feng Y,Zhang J,Pan Q,Long Z,Dai H,Cai F,Wu L,Zhao S,Chen Z,Xia J

更新日期：2004-12-01 00:00:00

abstract：:Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonl...

journal_title：Cancer gene therapy

authors： Chen X,Wang F,Wang T,Zhang Y,Ma X,Yuan L,Teng W,Guo L,Liu M,Liu M,Chen J,Nie D,Zhang Y,Zhou X,Wang M,Chen KN,Zhu P,Liu H

更新日期：2020-02-01 00:00:00

abstract：:The p16INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16INK4 gene transfer has been reported to be efficacious in inducing growth inhibition of various human tumors such as brain, lung, prostate, and esophageal cancer...

journal_title：Cancer gene therapy

authors： Campbell I,Magliocco A,Moyana T,Zheng C,Xiang J

更新日期：2000-09-01 00:00:00

abstract：:It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase repo...

journal_title：Cancer gene therapy

authors： Zhu ZB,Makhija SK,Lu B,Wang M,Kaliberova L,Liu B,Rivera AA,Nettelbeck DM,Mahasreshti PJ,Leath CA,Barker S,Yamaoto M,Li F,Alvarez RD,Curiel DT

更新日期：2004-04-01 00:00:00

abstract：:Sodium iodide symporter (NIS) reporter gene imaging is an excellent technology for noninvasive cell fate determination in living animals unless the NIS-transduced cells reside in perigastric organs such as the spleen, liver, diaphragm, omentum, pancreas, perigastric lymph nodes or perigastric tumor deposits. Here we r...

journal_title：Cancer gene therapy

authors： Suksanpaisan L,Pham L,McIvor S,Russell SJ,Peng KW

更新日期：2013-11-01 00:00:00

abstract：:Multicomponent lipoplexes have recently emerged as especially promising transfection candidates, as they are from 10 to 100 times more efficient than binary complexes usually employed for gene delivery purposes. Previously, we investigated a number of chemical-physical properties of DNA-lipid complexes that were propo...

journal_title：Cancer gene therapy

authors： Marchini C,Pozzi D,Montani M,Alfonsi C,Amici A,Candeloro De Sanctis S,Digman MA,Sanchez S,Gratton E,Amenitsch H,Fabbretti A,Gualerzi CO,Caracciolo G

更新日期：2011-08-01 00:00:00

abstract：:The human papillomaviruses (HPVs) are a diverse group of infectious agents, some of which are a causative agent of human cancers. Cervical cancer and oral cancer are closely associated with specific types of HPV, and the tumors grow only if there is continual expression of the viral E6 and E7 genes. Evidence from in v...

journal_title：Cancer gene therapy

authors： Shillitoe EJ

更新日期：2006-05-01 00:00:00

abstract：:Inflammation, among environmental risk factors, is one of the most important contributors to colorectal cancer (CRC) development. In this way, studies revealed that the incidence of CRC in inflammatory bowel disease patients is up to 60% higher than the general population. MicroRNAs (miRNAs), small noncoding RNA molec...

journal_title：Cancer gene therapy

authors： Karimzadeh MR,Zarin M,Ehtesham N,Khosravi S,Soosanabadi M,Mosallaei M,Pourdavoud P

更新日期：2020-11-01 00:00:00

abstract：:Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-relate...

journal_title：Cancer gene therapy

authors： Zhang W,Zhang Y,Yang Z,Liu X,Yang P,Wang J,Hu K,He X,Zhang X,Jing H

更新日期：2019-11-01 00:00:00

abstract：:Cancer gene therapy approaches are often designed as single-agent treatments; however, greater therapeutic effect might be obtained if combined with an established conventional treatment regimen such as chemotherapy. In this context, conditional promoters are useful tools, because they may be induced by therapeutic mo...

journal_title：Cancer gene therapy

authors： Walther W,Stein U,Fichtner I,Alexander M,Shoemaker RH,Schlag PM

更新日期：2000-06-01 00:00:00

abstract：:Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, ...

journal_title：Cancer gene therapy

authors： Choucair K,Morand S,Stanbery L,Edelman G,Dworkin L,Nemunaitis J

更新日期：2020-12-01 00:00:00

abstract：:Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to a...

journal_title：Cancer gene therapy

authors： Sanlioglu AD,Koksal IT,Karacay B,Baykara M,Luleci G,Sanlioglu S

更新日期：2006-01-01 00:00:00

abstract：:The herpes simplex virus thymidine kinase (HSV-TK) gene is being developed in the treatment of many different types of tumors. The HSV-TK gene sensitizes tumor cells to the antiviral drug ganciclovir (GCV) and mediates the bystander effect in which unmodified tumor cells are killed as well. Although this approach has ...

journal_title：Cancer gene therapy

authors： Whartenby KA,Darnowski JW,Freeman SM,Yurasha K,Calabresi P

更新日期：1999-09-01 00:00:00

abstract：:The original version of this Article contained an error in the spelling of the author Ahmed Abdelanabi, which was incorrectly given as Abdelanabi Ahmed. This has now been corrected in both the PDF and HTML versions of the Article. ...

journal_title：Cancer gene therapy

authors： Ahmed SG,Abdelanabi A,Doha M,Brenner GJ

更新日期：2020-04-01 00:00:00